GS
BCRX icon

George Soros’s BioCryst Pharmaceuticals BCRX Stock Holding History

George Soros’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-59,700
Closed -$632K – 373
2014
Q1 		$632K Buy
+59,700
New +$636K 0.01% 258

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

George Soros's BCRX Position: Q2 2014 in Review

George Soros sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2014, closing a stake of 59,700 shares — an estimated $632K sold.

George Soros first reported a position in BCRX in Q1 2014 and held it in 1 quarter. The position peaked at $632K in Q1 2014. 103 funds tracked by Wall St. Rank hold BCRX as of Q2 2014.

  • George Soros reported no remaining BioCryst Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • George Soros sold 59,700 BioCryst Pharmaceuticals shares in Q2 2014, an estimated $632K.
  • George Soros first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • George Soros's BioCryst Pharmaceuticals position peaked at $632K in Q1 2014.
  • 103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2014.

Based on Soros Fund Management's 13F filing for Q2 2014, filed 14 Aug 2014.